Efgartigimod

ApprovedRecruiting

1 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Myasthenia Gravis Crisis

Conditions

Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis

Trial Timeline

Mar 6, 2025 → Dec 31, 2026

NCT ID

NCT06860633

About Efgartigimod

Efgartigimod is a approved stage product being developed by Argenx for Myasthenia Gravis Crisis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06860633. Target conditions include Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis.

What happened to similar drugs?

1 of 20 similar drugs in Myasthenia Gravis Crisis were approved

Approved (1) Terminated (2) Active (17)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄tacrolimusAstellas PharmaPhase 3

🔄Tacrolimus capsule + PlaceboAstellas PharmaPhase 3

🔄tacrolimus + placeboAstellas PharmaPhase 3

🔄Cladribine Low Dose + Cladribine High DoseMerckPhase 3

🔄Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3

🔄IptacopanNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04777734	Pre-clinical	Completed	—	—	Generalized Myasthenia Gravis
NCT07011589	Phase 1/2	Recruiting	Jul 1, 2025	Oct 1, 2026	Epidermolysis Bullosa (EB)
NCT06860633	Approved	Recruiting	Mar 6, 2025	Dec 31, 2026	Myasthenia Gravis Crisis
NCT06298565	Pre-clinical	Recruiting	Nov 4, 2024	Jun 1, 2034	Myasthenia Gravis
NCT06299748	Pre-clinical	Recruiting	Nov 30, 2023	Dec 1, 2033	Myasthenia Gravis
NCT06203457	Phase 2	Completed	Nov 29, 2023	Feb 3, 2025	Primary Sjögren's Syndrome
NCT05918978	Phase 2	Terminated	Jun 20, 2023	Aug 15, 2024	Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome
NCT04274452	Phase 3	Withdrawn	Jun 29, 2020	Sep 1, 2021	Primary Immune Thrombocytopenia (ITP)
NCT04225156	Phase 3	Completed	Jun 2, 2020	Mar 11, 2026	Primary Immune Thrombocytopenia
NCT04188379	Phase 3	Completed	Dec 16, 2019	Feb 3, 2022	Primary Immune Thrombocytopenia

Competing Products

20 competing products in Myasthenia Gravis Crisis

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus capsule + Placebo	Astellas Pharma	Phase 3	40
tacrolimus + placebo	Astellas Pharma	Phase 3	40
Ravulizumab	AstraZeneca	Pre-clinical	33
Cladribine Low Dose + Cladribine High Dose	Merck	Phase 3	47
Remibrutinib (Blinded) + Remibrutinib (Open Label)	Novartis	Phase 3	47
Placebo + CFZ533	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	47
mycophenolate mofetil [CellCept] + Placebo	Roche	Phase 3	40
mycophenolate mofetil (CellCept) + placebo	Roche	Phase 3	40
inebilizumab + IV Placebo	Amgen	Phase 3	44
Inebilizumab	Amgen	Phase 2	42
Abatacept Injection	Bristol Myers Squibb	Phase 1	21
Tolebrutininb + Placebo	Sanofi	Phase 3	32
Pozelimab + Cemdisiran + Cemdisiran + Pozelimab	Regeneron Pharmaceuticals	Phase 3	44
HIZENTRA ®	CSL	Phase 2	35
Subcutaneous immunoglobulins	CSL	Phase 1	21
Human normal immunoglobulin G (IgG)	CSL	Phase 3	40
zilucoplan (RA101495)	UCB	Phase 3	44